Editorial: Nuclear Medicine in the Context of Personalized Medicine

Front Med (Lausanne). 2020 Jun 9:7:252. doi: 10.3389/fmed.2020.00252. eCollection 2020.

Jacques Barbet¹, Myriam Bernaudin², Pierre Payoux^{3

4}, Francesco Cicone^{5

6}, Marie-Hélène Gaugler⁷, Françoise Kraeber-Bodéré⁸

¹ GIP Arronax, Saint-Herblain, France.
² Université de Normandie, UNICAEN, CEA, CNRS, ISTCT/CERVOxy Group, GIP CYCERON, Caen, France.
³ Service de Médecine Nucléaire, CHU de Toulouse, Toulouse, France.
⁴ ToNIC, Toulouse NeuroImaging Center, UMR1214 Inserm, Toulouse, France.
⁵ Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
⁶ Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.
⁷ Université de Nantes, CNRS, Inserm, CRCINA, Nantes, France.
⁸ Université de Nantes, CHU de Nantes, ICO Gauducheau, CNRS, Inserm, CRCINA, Nantes, France.

No abstract available

Keywords: PET; hematological malignancies; radionuclide therapy; solid tumors; theranostics.

Publication types